FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

147 stories mentioning Eli Lilly and CompanyUpdated 6h ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.

$GSK$LLY$NRSN$NUVL
Wire

Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating

Jefferies Adjusts Eli Lilly Price Target to $1,350 From $1,330, Maintains Buy Rating

$LLY
Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure
US Markets

Eli Lilly Signs Alzheimer's Licensing Deal Worth Over $1 Billion With AlzeCure

Eli Lilly (LLY) shares were up early Tuesday as the drugmaker entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease.Under the terms of the deal, Lilly will pay $10 million upfront to AlzeCure, which will also be eligible for mid-single-digit royalties on sales, the Swedish company said. Development and commercial milestone payments could push the total value of the transaction above $1 billion, excluding royalties.Lilly's stock increased 1.1% in the most recent premarket activity.AlzeCure is developing Alzstatin ACD680, a gamma-secretase modulator, to reduce the production of the harmful amyloid-beta protein, which forms the building blocks of the amyloid plaques found in the brains of Alzheimer's patients, the company said."The Alzstatin compounds are hoped to be used to counteract re-accumulation of harmful amyloid in the brain," AlzeCure Chief Executive Martin Jonsson said in a statement. "In the long term, these compounds may also serve as a preventive treatment to prevent the development of Alzheimer's disease."The deal requires approval from regulatory authorities in Sweden, according to AlzeCure."The agreement with Lilly is an important milestone for AlzeCure and Alzstatin," Jonsson said.Lilly didn't immediately respond to a request for comment by.Lilly recently announced that its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea. The company also announced that overweight or obese women taking the highest dose of its obesity pill Foundayo, or orforglipron, lost weight across all stages of menopause in late-stage trials.

$LLY
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Johnson & Johnson (JNJ) eased 0.3% after the firm said it has agreed to buy cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 1%.Eli Lilly (LLY) shares rose 1.6% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Tango Therapeutics (TNGX) surged 51% after the firm said initial results from its phase 1/2 trial of vopimetostat plus Revolution Medicines' daraxonrasib showed a six-month progression-free survival rate of 90% in people with pancreatic cancer.

$INCY$JNJ$LLY$TNGX
Sectors

Sector Update: Healthcare Stocks Decline Monday Afternoon

Healthcare stocks were lower Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) fell 1%.In corporate news, Johnson & Johnson (JNJ) decreased 0.8% after the company said Monday that it has agreed to acquire cancer drug developer Firefly Bio for $1 billion in cash to strengthen its oncology portfolio.Incyte (INCY) agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, in a deal worth up to $2 billion, expanding its hematology portfolio into bleeding disorders. Shares fell 3%.Eli Lilly (LLY) shares rose 2.2% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and also showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$INCY$JNJ$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks eased Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.1%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Eli Lilly (LLY) shares rose 2.4% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.

$LLY
Wire

Top Midday Stories: US Weighs Financial Stakes in AI Firms; Google, Nvidia Turn to Intel as TSMC Struggles With Demand

All three major US stock indexes were up in late-morning trading Monday, after Iran's Ministry of Foreign Affairs said its military has ceased its strikes against Israel, though they could resume if Israeli operations in Lebanon continue.The US government is considering taking a financial stake in artificial intelligence companies, with President Donald Trump planning to meet with executives next week, news outlets reported late Friday, citing the president's comments aboard Air Force One.In company news, Alphabet's (GOOG, GOOGL) Google and Nvidia (NVDA) have turned to Intel (INTC) as a backup manufacturer for their most advanced processors as Taiwan Semiconductor Manufacturing (TSM) struggles to meet overwhelming demand, The Information reported Monday, citing four people with direct knowledge of the discussions. Google has placed an order for over 3 million Tensor Processing Units from Intel in 2028, the report said, citing two of the people. Nvidia hasn't placed an order with Intel, but its evaluating whether Intel technology can be used to make a processor that combines four graphics chips into a single unit, two of the people reportedly told The Information. Shares of Alphabet's Class C and Class A shares were both down 1.2% around midday. Nvidia shares were up 1%. Intel shares were up 12%, while TSM shares were up 3.5%.Eli Lilly (LLY) said Sunday that overweight or obese female patients reduced their body weight throughout all menopausal phases while using the maximum dose of its Foundayo medication in two medical trials. The first trial showed that pre-menopausal, perimenopausal and post-menopausal individuals dropped a maximum of 28 pounds, 30.4 pounds, and 28.2 pounds over 72 weeks, the company said. During the second study focusing on subjects with type 2 diabetes, patients in the same three physiological stages shed up to 23.4 pounds, 18.5 pounds, and 27.8 pounds, the company said. Separately, the company reported Saturday that additional phase 3 data showed that its investigational molecule retatrutide achieved substantial weight loss with meaningful improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes. Eli Lilly shares were up 2.6%.Amazon (AMZN) said Monday it signed a multibillion-dollar deal with Corning (GLW) to supply optical fiber, cable and connectivity products for its growing US data center network. Amazon shares were down 0.1%, while Corning shares were up 6.3%.SpaceX (SPCX) has attracted about $150 billion in investor demand for its initial public offering, about twice the $75 billion it aims to raise, Reuters reported Sunday, citing people familiar with the matter.Tango Therapeutics (TNGX) said Monday that initial results from its phase 1/2 trial of vopimetostat, an investigational PRMT5 inhibitor, in combination with Revolution Medicines inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer. Tango shares were up 47%.Campbell's (CPB) reported fiscal Q3 adjusted earnings Monday of $0.50 per diluted share, down from $0.73 a year earlier but above the FactSet consensus analyst estimate of $0.48. Fiscal Q3 net sales were $2.37 billion, down from $2.48 billion a year ago and below the FactSet consensus of $2.38 billion. Campbell's shares were down 1.2%.Price: $207.86, Change: $+2.76, Percent Change: +1.35%

$AMZN$CPB$GLW$GOOG$GOOGL$INTC$LLY$NVDA$TNGX$TSM
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Chip Stocks Rebound

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.9% in Monday's premarket activity, as semiconductor shares rebound from Friday's selloff.US stock futures were also higher, with S&P 500 Index futures up 0.8%, Dow Jones Industrial Average futures advancing 0.3%, and Nasdaq futures gaining 1.4% before the start of regular trading.The New York Fed's inflation expectations report for May will be released at 11 am ET.In premarket action, bitcoin was up by 3.8%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.4% higher, Ether ETF (EETH) advanced 6.8%, and Bitcoin & Ether Market Cap Weight ETF (BETH) retreated by 0.01%.Power Play:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.8% and the iShares US Industrials ETF (IYJ) was inactive.Graham (GHM) stock was down more than 7% before the opening bell after the company reported lower fiscal Q4 adjusted net income.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 1.8%, and the iShares US Technology ETF (IYW) was 1.8% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 1.8%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 3.8%, while the iShares Semiconductor ETF (SOXX) rose by 4.1%.Nvidia (NVDA) shares were up more than 2% in premarket activity after dropping by 6.2% on Friday. The company will expand artificial intelligence infrastructure in South Korea, beginning with a 55-megawatt deployment at Naver's GAK Sejong data center. The chipmaker also closed a multi-year deal with SK hynix to design future generations of artificial intelligence memory hardware.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.2% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.8%. The iShares US Consumer Staples ETF (IYK) advanced by 0.1%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) gained 0.8%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) rose by 1%.Ingredion (INGR) shares were up 0.8% pre-bell after the company said it has launched an all-cash tender offer to acquire Tate & Lyle, valuing the specialty ingredients company at about 3.7 billion British pounds ($5 billion).HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) was down 0.2%, while the iShares US Healthcare ETF (IYH) slipped 0.2%. The iShares Biotechnology ETF (IBB) was 0.2% higher.Eli Lilly (LLY) stock was up more than 1% premarket after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Blackstone (BX) shares were up 0.4% pre-bell after closing Friday with a 2.7% fall. The Financial Times reported the company is preparing to offload more than $2 billion in private fund stakes through a structured bond deal.EnergyThe iShares US Energy ETF (IYE) was up 0.7%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.7%.Eni (E) stock was up nearly 1% before the opening bell, following a 1.1% decline in the prior trading session. Petronas and Eni said they have launched a new 50/50 joint venture called Searah that will combine businesses across Indonesia and Malaysia.CommoditiesFront-month US West Texas Intermediate crude oil gained by 0.9% to $91.33 per barrel on the New York Mercantile Exchange. Natural gas was down 2.9% to $3.13 per 1 million British Thermal Units. The United States Oil Fund (USO) advanced by 2%, while the United States Natural Gas Fund (UNG) was 2.4% lower.Gold futures for July retreated by 0.3% to $4,354.00 an ounce on the Comex. Silver futures declined by 0.7% to $68.60 an ounce. SPDR Gold Shares (GLD) was up by 0.2%, and the iShares Silver Trust (SLV) increased by 0.5%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BX$E$EEM$EETH$EXI$FAS$FAZ$GHM$GLD$IBB$IGM$IGV$INGR$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$LLY$NVDA$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare Stocks Steady Pre-Bell Monday

Healthcare stocks were steady pre-bell Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up a slight 0.1%.Tango Therapeutics (TNGX) shares were up more than 45% after the company said initial results from its phase 1/2 trial of vopimetostat in combination with Revolution Medicines' inhibitor daraxonrasib showed a six-month progression-free survival rate of 90% in patients with pancreatic cancer.Eli Lilly (LLY) shares were up more than 2% after the company said additional phase 3 data showed that retatrutide achieved substantial weight loss with "meaningful" improvements in obesity-related conditions, including knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, and type 2 diabetes.Shattuck Labs (STTK) said its phase 1 study of SL-325, a treatment for immune-related disease, showed good safety results and consistent drug performance in healthy volunteers. Shattuck Labs stock was up more than 14% premarket.

$IBB$LLY$STTK$TNGX$XLV
Asia Markets

US Equity Futures Higher Pre-Bell as Trump Tries to Keep Fragile Middle East Ceasefire Intact Amid New Israel-Iran Clashes

US equity futures were edging higher pre-bell Monday as President Donald Trump tried to hold together the fragile Middle East ceasefire after Israel and Iran exchanged attacks over the past few days.Dow Jones Industrial Average futures were 0.3% higher, S&P 500 futures were up 0.8%, and Nasdaq futures were 1.4% higher.In a post on Truth Social, Trump said that Israel and Iran were looking to do an "immediate" ceasefire after the two nations exchanged a series of attacks. Israeli forces on Sunday had launched strikes on Iran-backed Hezbollah forces inside Beirut, Lebanon, and Iran had retaliated with missile attacks. "The Blockade will remain in place, and in full force and effect, until a 'Final Deal' is reached," Trump said.The US imposed a blockade of Iranian ports after Iran barred transit of ships in the Strait of Hormuz.Oracle (ORCL) and Adobe (ADBE) are among the companies scheduled to release quarterly financial results within the week.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 1.8% at $94.74 per barrel and US West Texas Intermediate crude 1.4% higher at $91.82 per barrel.The NY Federal Reserve's June consumer inflation expectations index is scheduled to be released at 11 am ET.In other world markets, Japan's Nikkei closed 3.9% lower, Hong Kong's Hang Seng ended 1.2% lower, and China's Shanghai Composite finished 1.7% lower. Meanwhile, the UK's FTSE 100 was up 0.1%, and Germany's DAX index was 0.3% lower in Europe's early afternoon session.In equities, Nvidia (NVDA) shares rose 2.4% after a Bloomberg report cited company CEO Jensen Huang as saying that a global technology stock selloff was an opportunity to purchase shares at a discount. Eli Lilly (LLY) stock was up 1.7% after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea. Advanced Micro Devices (AMD) stock was up 3.7% after the company said it plans to invest up to 2 billion British Pounds ($2.7 billion) in the UK over the next five years to accelerate artificial intelligence research.On the losing side, Haleon (HLN) shares dropped 1% after the company said it plans to invest about 175 million pounds ($233.1 million) to build a new oral health manufacturing facility in Madhya Pradesh and expand distribution across rural India.

Dow JonesNasdaq CompositeS&P 500$ADBE$AMD$HLN$LLY$NVDA$ORCL
Stocks Mostly Up Pre-Bell as Traders Assess Renewed Middle East Tensions, Await Key Inflation Data
US Markets

Stocks Mostly Up Pre-Bell as Traders Assess Renewed Middle East Tensions, Await Key Inflation Data

The benchmark US stock measures were mostly pointing higher before the opening bell Monday as investors weigh tensions after Iran and Israel exchanged strikes and await key inflation data later this week.The S&P 500 increased 0.4% and the Nasdaq added 0.8% in premarket activity, while the Dow Jones Industrial Average edged down less than 0.1%. The indexes finished Friday's trading session in the red, with the Nasdaq reportedly recording its biggest one-day decline since April 2025.Iran launched a fresh wave of airstrikes against Israel on Monday, Bloomberg News reported. Israel responded with strikes on military targets in western and central Iran, while Iranian state media reported multiple explosions in Tehran, according to Bloomberg.Tensions between the two countries escalated after Iran launched missiles toward Israel over the weekend in retaliation for Israeli strikes on the southern suburbs of Beirut, Lebanon.President Donald Trump told Israeli Prime Minister Benjamin Netanyahu not to retaliate against Iran's attack and allow time for more diplomacy, Axios reported Sunday, citing a senior US official and an Israeli source.An Iranian official involved in the discussions between Washington and Tehran told MS NOW that a peace deal with Trump is "no longer feasible" after the latest exchange of fire.West Texas Intermediate crude oil jumped 3.8% to $94.02 a barrel before the open, while Brent gained 3.6% to $96.43.With no major economic reports scheduled for Monday, traders will turn their attention to the consumer price index for May on Wednesday, followed by data on wholesale prices for the same month on Thursday.On Friday, the Bureau of Labor Statistics reported that total nonfarm payrolls in the US rose by 172,000 in May, nearly double the 88,000 increase expected in a Bloomberg-compiled survey.Treasury yields were trending upwards in premarket action, with the two-year rate rising 0.2 basis points to 4.16% and the 10-year rate inclining 1.8 basis points to 4.55%.Eli Lilly's (LLY) shares advanced 3.9% pre-bell after the drugmaker said its investigational drug for obesity, retatrutide, showed "substantial" weight loss in two clinical studies, as well as "meaningful" improvements in knee osteoarthritis pain and sleep apnea.Oracle (ORCL) and Adobe (ADBE) are scheduled to report their latest financial results later this week. Campbell's (CPB) posts its earnings before the bell Monday.Gold declined 0.9% to $4,325 per troy ounce, while bitcoin climbed 2.9% to $63,118.

Dow JonesNasdaq CompositeS&P 500$ADBE$CPB$LLY$ORCL
Eli Lilly Says Obesity Drug Delivers Significant Weight Loss, Improves Knee Pain and Sleep Apnea in Trials
US Markets

Eli Lilly Says Obesity Drug Delivers Significant Weight Loss, Improves Knee Pain and Sleep Apnea in Trials

Eli Lilly (LLY) shares rose early Monday after the drugmaker said its experimental obesity drug retatrutide delivered significant weight loss in two clinical studies and showed "meaningful" improvements in knee osteoarthritis pain and sleep apnea.The company conducted two phase-three studies of retatrutide, involving 2,876 patients, according to a statement on Saturday.In one of the trials in adults with obesity, participants given the highest 12 mg dose of retatrutide lost an average of 28.3% of their body weight over 80 weeks, according to Lilly. About 65.3% of patients on the high dose achieved a body mass index below 30, no longer meeting the criteria for obesity, the company said.The study also showed that the drug reduced knee osteoarthritis pain by up to 73.1% and cut moderate-to-severe obstructive sleep apnea severity by up to 36.1 events per hour, or 60.6%.The stock gained 4.4% in the most recent premarket activity."Across triumph-1 and transcend-T2D-1, retatrutide delivered substantial weight loss, meaningful (glycated hemoglobin) reduction, and improvements in knee osteoarthritis pain and moderate-to-severe obstructive sleep apnea," Kenneth Custer, executive vice president at Lilly Cardiometabolic Health, said in the statement. "These results highlight retatrutide's potential across the cardiometabolic spectrum."In a second clinical study in adults with type 2 diabetes, retatrutide met its primary endpoint, reducing glycated hemoglobin by up to 2% and body weight by up to 16.8% at 40 weeks.In a separate statement Sunday, the company said overweight or obese women taking the highest dose of its obesity pill Foundayo, or orforglipron, lost weight across all stages of menopause in late-stage trials. In April, the US Food and Drug Administration approved Foundayo for adults with obesity or overweight with weight-related medical problems.

$LLY
Sectors

Sector Update: Healthcare Stocks Climb Late Afternoon

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 3%.The iShares Biotechnology ETF (IBB) added 2.6%.In corporate news, Eli Lilly (LLY) shares gained 4.3% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares climbed 5% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.The US Supreme Court on Thursday ruled that Amarin (AMRN) failed to prove that a generic-drug manufacturer actively induced other companies to infringe upon two of its Vascepa patents after the generic maker received approval for a so-called "skinny-label" version of the drug. Amarin shares fell 4.4%.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improve and "supportive" near-term data points form a favorable Q2. UnitedHealth shares rose 5.4%.

$AMRN$LLY$MRK$UNH
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index climbing 3.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.8%.The iShares Biotechnology ETF (IBB) added 2.2%.In corporate news, Eli Lilly (LLY) shares climbed 5% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.Merck (MRK) shares rose 3.9% after it said Thursday it will pay over $50 million to settle more than 200 lawsuits that blame the drugmaker's Gardasil cancer vaccine for causing autoimmune ailments in young women, Bloomberg reported.BofA Securities upgraded UnitedHealth (UNH) to buy from neutral as medical cost trends improvement and "supportive" near-term data points form a favorable Q2. UnitedHealth shares gained 5.2%.

$LLY$MRK$UNH
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index climbing 3.3% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 2.9%.The iShares Biotechnology ETF (IBB) added 2.4%.In corporate news, Eli Lilly (LLY) shares climbed 5.1% after Ascidian Therapeutics said Lilly will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a research partnership and licensing deal.

$LLY
Asia Markets

US Equity Futures Mixed Pre-Bell as Broadcom Falls, Clashes Continue in Middle East

US equity futures were mixed pre-bell Thursday as traders watched tech giant Broadcom's (AVGO) stock drop after the company posted its fiscal Q2 financial results and attacks continued in the Middle East.Dow Jones Industrial Average futures were 0.9% higher, S&P 500 futures were down 0.4%, and Nasdaq futures were 1.2% lower.Broadcom shares were down 15% in premarket activity as the company issued below-consensus guidance for fiscal Q3 AI-chip revenue.Kuwait reported that an Iranian missile and drone strike hit the country's international airport, killing one person and injuring dozens more. Iran claimed that it launched a retaliatory attack on US military bases in Kuwait after an earlier set of airstrikes by US forces.Traders also digested the latest round of earnings, with CrowdStrike (CRWD) posting higher fiscal Q1 adjusted earnings and revenue.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 3% at $94.89 per barrel and US West Texas Intermediate crude 3.2% lower at $92.97 per barrel.The weekly jobless claims bulletin, released at 8:30 am ET, showed 225,000 new unemployment claims for the week ended May 2, compared with the downwardly revised figure of 212,000 in the prior week, and it came in above the 215,000 expected, according to estimates compiled by Bloomberg. Q1 nonfarm productivity increased at a 0.3% annual rate, below forecasts for 0.4%, while unit labor costs increased 1.8%, compared with the 2.4% expected.Federal Reserve Richmond President Thomas Barkin and San Francisco President Mary Daly are slated to speak on Thursday.In other world markets, Japan's Nikkei closed 1.4% lower, Hong Kong's Hang Seng ended 1.5% lower, and China's Shanghai Composite finished 0.6% lower. Meanwhile, the UK's FTSE 100 was down 0.2%, and Germany's DAX index was 0.6% higher in Europe's early afternoon session.In equities, CrowdStrike stock was down 10% after the company reported its fiscal Q1 financial results. ARM (ARM), Micron Technology (MU), and Marvell Technology (MRVL) shares were all down as part of a broader stock sell-off in the semiconductor industry. ARM shares fell 6%, Micron stock was down 6.4%, and Marvell shares dropped 5.9%.On the winning side, Eli Lilly (LLY) was up 1.3% after Ascidian Therapeutics said the company will receive exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed kidney disease targets in exchange for up to $1.9 billion under a new research partnership and licensing agreement. Costco Wholesale (COST) shares rose 2.3% after the company reported net sales of $24.01 billion for May, up from $20.97 billion a year earlier. RTX (RTX) stock was up 2.2% after the company said that its Raytheon unit was awarded a $515 million contract from the US Navy for the SPY-6 family of radars.

Dow JonesNasdaq CompositeS&P 500$ARM$AVGO$COST$CRWD$LLY$MRVL$MU$RTX
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.5%.The iShares Biotechnology ETF (IBB) climbed 1.5%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 4.3%.Agilent Technologies (A) stock jumped 18% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 5% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.AstraZeneca's (AZN) durvalumab, plus Bacillus Calmette-Guerin, received approval by the Food and Drug Administration to treat adults with BCG-naive, high-risk non-muscle invasive bladder cancer, the FDA said Thursday. AstraZeneca shares rose 0.2%.

$A$AZN$ILMN$LLY
Sectors

Sector Update: Healthcare Stocks Gain Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) increased 1.1%.In corporate news, Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Lilly shares gained 3.6%.Agilent Technologies (A) stock jumped 19% after the company posted higher fiscal Q2 adjusted earnings and revenue, and raised its fiscal 2026 adjusted EPS guidance.Illumina (ILMN) shares climbed 4.9% after it said it launched a whole-genome sequencing research workflow for molecular residual disease detection.Cogent Biosciences (COGT) shares added 2.4% after it said the US Food and Drug Administration has accepted its new drug application for bezuclastinib plus sunitinib to treat patients with gastrointestinal stromal tumors who have been treated with imatinib previously.

$A$COGT$ILMN$LLY
Wire

Top Midday Stories: US Reportedly Reaches Deal With Iran, Needs Trump's Approval; Caesars to be Acquired by Fertitta for $17.6 Billion

The S&P 500 and Nasdaq Composite were up, while the Dow Jones Industrial Average was down slightly in late-morning trading Thursday after Axios reported that US and Iranian negotiators have reached an agreement on a 60-day memorandum of understanding that extends the ceasefire and launches negotiations on Iran's nuclear program. The deal is waiting the final approval of President Donald Trump, the report said.The personal consumption expenditures index rose by 0.4% in April, below the 0.5% gain expected, lifting the year-over-year rate to 3.8% from 3.5%. The core PCE price index, which excludes gas and food prices, increased by 0.2%, below the 0.3% gain expected and following a 0.3% gain in March. The year-over-year rate accelerated to 3.3% from 3.2% in the previous month.In company news, Caesars Entertainment (CZR) has agreed to be acquired by Fertitta Entertainment in an all-cash deal valued at $17.6 billion, including the assumption of around $11.9 billion of outstanding debt, Caesars said Thursday. Under the terms of the deal, Caesars shareholders will receive $31 in cash for each share owned, the company said. Caesars shares were up 1.3% around midday.Snowflake (SNOW) reported fiscal Q1 adjusted net income late Wednesday of $0.39 per diluted share, up from $0.24 a year earlier and above the FactSet consensus analyst estimate of $0.32. Fiscal Q1 revenue was $1.39 billion, up from $1.04 billion a year ago and above the FactSet consensus of $1.32 billion. For fiscal Q2, the company said it expects product revenue of $1.415 billion to $1.420 billion, above the FactSet consensus of $1.37 billion. Snowflake shares were up 34.0%.Salesforce (CRM) reported fiscal Q1 adjusted earnings late Wednesday of $3.88 per diluted share, up from $2.58 a year earlier and above the FactSet consensus of $3.13. Fiscal Q1 revenue was $11.13 billion, up from $9.83 billion a year ago and above the FactSet consensus of $11.05 billion. For fiscal Q2, the company said it expects adjusted EPS of $3.25 to $3.27 on revenue of $11.27 billion to $11.35 billion. Analysts polled by FactSet expect $3.25 and $11.35 billion, respectively. Separately, Salesforce will deploy its AI-driven Agentforce Health platform to improve efficiency at CVS Health (CVS) call centers, the companies said Thursday. Salesforce shares were up 0.4%, while CVS shares were up 1.3%.Marvell Technology (MRVL) reported fiscal Q1 adjusted earnings late Wednesday of $0.80 per diluted share, up from $0.62 a year earlier and in line with the FactSet consensus. Fiscal Q1 revenue was $2.42 billion, up from $1.9 billion a year ago and above the FactSet consensus of $2.41 billion. For fiscal Q2, the company said it expects adjusted EPS of $0.93, plus or minus $0.05, on revenue of $2.7 billion, plus or minus 5%. Analysts polled by FactSet expect $0.90 and $2.6 billion, respectively. Marvell shares were down 1.3%.Canadian Imperial Bank of Commerce (CM) reported fiscal Q2 adjusted earnings Thursday of 2.54 Canadian dollars ($1.83) per diluted share, up from CA$2.05 a year earlier and above the FactSet consensus of CA$2.46. Fiscal Q2 revenue was CA$8.01 billion, up from CA$7.02 billion a year ago. The bank said it plans to buy for cancellation up to 30 million shares, representing about 3.3% of total outstanding shares. Also, the company has agreed to sell its 91.7% stake in CIBC Caribbean Bank to Bank of N.T. Butterfield & Son (NTB) for a total consideration of about $1.6 billion, the acquiring company said. CIBC shares were down 4.6%.Best Buy (BBY) reported fiscal Q1 adjusted earnings Thursday of $1.28 per diluted share, up from $1.15 a year earlier and above the FactSet consensus of $1.23. Fiscal Q1 revenue was $8.94 billion, up from $8.77 billion a year ago and above the FactSet consensus of $8.83 billion. The company reiterated its fiscal 2027 guidance for adjusted EPS of $6.30 to $6.60 and revenue of $41.20 billion to $42.10 billion. Best Buy shares were up 16.3%.Eli Lilly's (LLY) weight-loss drugs secured coverage from the three largest US pharmacy benefit managers, the drugmaker said Thursday. Coverage for Foundayo through CVS Health's CVS Caremark Commercial Template plans will begin Monday, while access for existing Zepbound patients will continue without interruption and expand further by Oct. 1, the company said. Eli Lilly shares were up 4.1%.Price: $29.15, Change: $+0.36, Percent Change: +1.27%

$BBY$CM$CRM$CVS$CZR$LLY$MRVL$NTB$SNOW
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Eli Lilly And Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target to $1,255 from $1,225, 28.9x our 2027 EPS view, below LLY's five-year historical forward P/E average. We lift our 2026 EPS to $37.03 from $36.97 and raise our 2027 EPS to $43.42 from $42.22. We think LLY's continuous focus on external innovation to diversify its pipeline remains a key differentiator versus peers. LLY announced three vaccine deals today as part of a strategic push into infectious disease prevention. LLY is acquiring Curevo for up to $1.5B, gaining access to amezosvatein, a next-gen shingles vaccine that demonstrated comparable efficacy to the current standard while reducing side effects in Phase 2 trials. LLY is also acquiring LimmaTech Biologics for up to $780M, bringing a bacterial vaccine platform targeting antimicrobial-resistant pathogens. LLY is also acquiring Vaccine Company for up to $1.55B, adding an in vivo nanoparticle tech platform and a Phase 1-ready Epstein-Barr Virus vaccine candidate addressing a pathogen linked to multiple sclerosis and certain cancers.

$LLY

Showing 61-80 of 147

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company
Eli Lilly and Company (LLY) News | FINWIRES